Cadence has raised $100 million in a Series C funding round to accelerate the expansion of its artificial intelligence-powered chronic disease management platform, strengthening its presence across health systems and advancing value-based care initiatives. Led by Spark Capital, the financing also drew participation from Thrive Capital, General Catalyst, Coatue, B Capital, Corewell Health Ventures, Memorial Hermann and Duke Health. The latest investment follows the company’s $100 million Series B round completed in December 2021. The funding will be directed toward enhancing its AI agents, expanding value-based care programs and bringing its platform to additional health systems. Spark Capital Partner and Cadence board member Will Reed said, “the most consequential AI companies of the next decade” will be those built for areas where “technology changes the underlying mechanics of the business.” Reed added, “Cadence has done the hardest work first—demonstrating clinical outcomes, building trust with the country’s leading health systems, and proving out the safe and effective deployment of AI inside care delivery. There is no other AI care platform in the country with this combination of scale, peer-reviewed clinical outcomes, and economic proof.” The company positions AI chronic care as a core element of its long-term growth strategy.
Cadence’s Clinical Intelligence platform is designed to identify patient risks early while supporting older adults between clinical visits through daily vital monitoring, medication adjustment assistance and personalized lifestyle coaching. The platform integrates directly with partner health systems, medical groups, electronic medical records (EMRs) and existing clinical workflows, where supervised AI agents monitor patient health and assist care teams with timely interventions. Founder and CEO Chris Altcheck said the platform was built to “solve the clinical labor constraint at the heart of the chronic disease crisis.” He further stated, “Our AI automates care under close supervision, guided by our medical group, governed by our health system clinical protocols, and reimbursed through billing infrastructure and at-risk contracts. We’re treating 100,000 patients with that system today, alongside partners committed to changing the status quo in chronic care. This investment builds the infrastructure to treat millions.”
The company currently collaborates with more than 20 health systems and provides care for over 100,000 active patients. According to company executives, Cadence tripled annual recurring revenue during 2025 while helping save Medicare approximately $2.7 million each week. Alongside the funding announcement, the company revealed new affiliations with Duke Health and Texas Health Resources. Jeffrey Ferranti, M.D., senior vice president and chief digital officer of Duke Health, said, “At Duke Health, our mission is to advance the health of our patients and the communities we serve. The moments that matter most for a patient’s health often happen at home, not in the clinic. With Cadence, we stay connected to patients with chronic conditions around the clock, monitoring their health continuously so we can intervene early and keep them healthy. Together, we’re reimagining what care can be: healthier patients and a stronger, more affordable health system for all.” Cadence also highlighted peer-reviewed evidence supporting its platform, including a Mayo Clinic study reporting a 27% reduction in hospital admissions and a $1,302 annual reduction in total care costs per patient, while research published in the Journal of the American College of Cardiology found its remote patient care hypertension program achieved a 70% improvement in blood pressure control. These findings reinforce the company’s approach to AI chronic care.
